CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0.96×, higher than 95% of its Biotechnology peers (median 0.07×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
717.85MUSDvs all stocks (USD)
Revenue (TTM)
132.42MUSDvs all stocks (USD)
Profit Margin
-219.61%vs Biotechnology peers
Beta
1.77xvs all stocks
52-Week Change
-19.43%vs all stocks
Market Capitalization
717.85MUSDvs all stocks (USD)
Enterprise Value
819.80MUSDvs all stocks (USD)
Forward P/E
-3.68xvs Biotechnology peers
Price to Sales (TTM)
5.42xvs Biotechnology peers
Price to Book (MRQ)
1.62xvs Biotechnology peers
Enterprise to Revenue
6.19xvs Biotechnology peers
Enterprise to EBITDA
-3.13xvs Biotechnology peers
Gross Margin
91.47%vs Biotechnology peers
Profit Margin
-219.61%vs Biotechnology peers
Operating Margin
-284.99%vs Biotechnology peers
Return on Assets (TTM)
-16.72%vs Biotechnology peers
Return on Equity (TTM)
-59.94%vs Biotechnology peers
Revenue (TTM)
132.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.26USDUpdated Sep 27, 2026Quarterly Revenue Growth
-48.50%vs Biotechnology peers
Gross Profit (TTM)
90.10MUSDvs all stocks (USD)
EBITDA (TTM)
-261.62MUSDvs all stocks (USD)
Net Income (TTM)
-309.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-59.37%vs Biotechnology peers
Operating Cash Flow (TTM)
-170.24MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-72.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
170.16MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
46.97MUSDFY2025 · Dec 31, 2025Gross Profit
123.18MUSDFY2025 · Dec 31, 2025Operating Income
-303.88MUSDvs all stocks (USD)
Pre-tax Income
-313.60MUSDFY2025 · Dec 31, 2025Income Tax Expense
-837.00KUSDFY2025 · Dec 31, 2025Net Income
-312.76MUSDFY2025 · Dec 31, 2025EBIT
-313.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-226.80MUSDFY2025 · Dec 31, 2025Research & Development
243.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
183.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-5.64USDFY2025 · Dec 31, 2025EPS (Diluted)
-5.64USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.46MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.46MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-312.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-189.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-196.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
212.37MUSDFY2025 · Dec 31, 2025Income Tax Paid
192.00KUSDFY2025 · Dec 31, 2025Interest Paid
4.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-312.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
58.99MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.36MUSDFY2025 · Dec 31, 2025Stock-based Compensation
81.55MUSDFY2025 · Dec 31, 2025Other Non-cash Items
33.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.47MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.99MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-44.75MUSDFY2025 · Dec 31, 2025Capital Expenditures
-7.09MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-418.63MUSDFY2025 · Dec 31, 2025Sale of Investments
185.38MUSDFY2025 · Dec 31, 2025Other Investing Activity
50.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-240.29MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-354.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
63.71MSharesUpdated Sep 27, 2026Float Shares
49.88MSharesUpdated Sep 27, 2026Shares Short
7.17MSharesUpdated Sep 27, 2026Short Ratio
6.35daysvs all stocks
Short % of Shares Outstanding
13.36%vs all stocks
% Held by Insiders
4.43%vs all stocks
% Held by Institutions
73.72%vs all stocks
Total Cash (MRQ)
302.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.49USDUpdated Sep 27, 2026Total Debt (MRQ)
404.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9615xvs Biotechnology peers
Current Ratio (MRQ)
4.57xvs Biotechnology peers
Book Value per Share (MRQ)
6.60USDUpdated Sep 27, 2026Total Assets
1.12BUSDvs all stocks (USD)
Total Current Assets
471.84MUSDFY2025 · Dec 31, 2025Total Liabilities
611.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
647.86MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
515.14MUSDFY2025 · Dec 31, 2025Total Current Liabilities
95.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
167.20MUSDFY2025 · Dec 31, 2025Other Short-term Investments
255.42MUSDFY2025 · Dec 31, 2025Accounts Receivable
24.03MUSDFY2025 · Dec 31, 2025Accounts Payable
10.57MUSDFY2025 · Dec 31, 2025Short-term Debt
22.81MUSDFY2025 · Dec 31, 2025Deferred Revenue
19.98MUSDFY2025 · Dec 31, 2025Other Current Liabilities
27.05MUSDFY2025 · Dec 31, 2025Long-term Debt
417.08MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
22.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-6.15BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
508.59MUSDvs all stocks (USD)
52-Week Low
5.37USDUpdated Sep 27, 202652-Week High
17.58USDUpdated Sep 27, 202652-Week Change
-19.43%vs all stocks
Beta
1.77xvs all stocks
50-Day MA
7.61USDUpdated Sep 27, 2026200-Day MA
8.25USDUpdated Sep 27, 2026Avg 10-Day Volume
2.03MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.46MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-5.33USDUpdated Sep 27, 2026Other Income / Expense
-32.34MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Rising Operating Income With Falling Gross Profit and Shrinking Assets
Operating income has risen while gross profit and the asset base both shrank.
Reads
Diagnostic
Operating Income Up Despite Gross Profit Decline, Margins Elevated
Operating income keeps rising while gross profit falls, so the gain sits below that line.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0.96×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 0.96Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.91Profit Margin: -2.20
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
XOMA Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
OmniAb, Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Model Organisms Center Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Angi Inc.
2 interpretationsOperating Income Up Despite Gross Profit Decline, Margins ElevatedRising Operating Income With Falling Gross Profit and Shrinking Assets
Stitch Fix Inc.
2 interpretationsOperating Income Up Despite Gross Profit Decline, Margins ElevatedRising Operating Income With Falling Gross Profit and Shrinking Assets